Univariable and multivariable logistic and Cox regression analyses of risk factors associated with RR, PFS, and OS

RR*PFS#OS$
Univariable analysisMultivariable analysisUnivariable analysisMultivariable analysisUnivariable analysisMultivariable analysis
OR (95% CI)p-valueOR (95% CI)p-valueHR (95% CI)p-valueHR (95% CI)p-valueHR (95% CI)p-valueHR (95% CI)p-value
Heng Prognostic Score
 LowReferenceReferenceReferenceReferenceReferenceReference
 Int/High^0.500 (0.124,1.973)0.3190.553 (0.130,2.322)0.4140.779 (0.379,1.6)0.4960.892 (0.433,1.837)0.7570.514 (0.182,1.451)0.2010.559 (0.197,1.585)0.274
Duration of prior anti-VEGF Therapies
 < 6 MonthsReferenceReferenceReferenceReferenceReferenceReference
 ≥ 6 Months2.200 (0.613,8.678)0.2372.362 (0.627,9.979)0.2162.015 (1.046,3.883)0.0482.288 (1.094,4.785)0.0282.869 (0.9,9.141)0.0632.913 (0.904,9.388)0.073
Pretherapy NLR
 < 3ReferenceReferenceReferenceReferenceReferenceReference
 ≥ 32.567 (0.717,10.16)0.1582.538 (0.674,10.57)0.1782.67 (1.343,5.308)0.0042.937 (1.444,5.972)0.0033.977 (1.227,12.889)0.0144.01 (1.189,13.524)0.025

^, Intermediate and high; *, PD1/PDL1 response rate to progression disease and non-response; #, progression-free survival; $, overall survival